KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Jazz Pharmaceuticals (JAZZ) Cost of Revenue (2016 - 2025)

Jazz Pharmaceuticals (JAZZ) has 16 years of Cost of Revenue data on record, last reported at $128.9 million in Q3 2025.

  • For Q3 2025, Cost of Revenue rose 15.47% year-over-year to $128.9 million; the TTM value through Sep 2025 reached $485.5 million, up 14.43%, while the annual FY2025 figure was $503.3 million, 12.92% up from the prior year.
  • Cost of Revenue reached $128.9 million in Q3 2025 per JAZZ's latest filing, up from $116.3 million in the prior quarter.
  • Across five years, Cost of Revenue topped out at $167.4 million in Q4 2022 and bottomed at $40.2 million in Q1 2021.
  • Average Cost of Revenue over 5 years is $117.1 million, with a median of $117.7 million recorded in 2021.
  • Peak YoY movement for Cost of Revenue: skyrocketed 325.57% in 2021, then plummeted 35.92% in 2023.
  • A 5-year view of Cost of Revenue shows it stood at $136.2 million in 2021, then grew by 22.92% to $167.4 million in 2022, then plummeted by 35.92% to $107.2 million in 2023, then increased by 20.02% to $128.7 million in 2024, then grew by 0.13% to $128.9 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cost of Revenue were $128.9 million in Q3 2025, $116.3 million in Q2 2025, and $128.7 million in Q4 2024.